Results 181 to 190 of about 72,745 (302)

The FOXC2‐LAMA4 Axis Orchestrates Vasculogenic Mimicry and Immunosuppressive Niche Formation to Drive Metastatic Cascade in Renal Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
Advanced clear cell renal cell carcinoma metastasis is driven by a FOXC2+ tumor subpopulation. These cells execute vasculogenic mimicry for dissemination and secrete LAMA4. LAMA4 engages macrophage ITGA6, activating the STAT6/GATA3 axis to polarize macrophages into a pro‐metastatic, immunosuppressive phenotype.
Jiaxi Yao   +11 more
wiley   +1 more source

Precise Construction of an Antimicrobial Peptide Targeting Bacterial Cell Membranes Derived From Natural Peptides

open access: yesAdvanced Science, EarlyView.
An AMP (P 3‐3R‐8I) based on natural peptides, which can target bacterial cell membranes, was precisely constructed via amino acid mutation. P 3‐3R‐8I exhibits antibacterial capability which could be attributed to the ability of P 3‐3R‐8I to quickly penetrate bacterial cell membranes and then to bind to bacterial DNA.
Jiaqi Huang   +11 more
wiley   +1 more source

Evaluation of immunological abnormalities in patients with rare syndromes

open access: yesCentral European Journal of Immunology, 2023
Yahya Gul   +7 more
doaj   +1 more source

Subcutaneous immunoglobulin replacement therapy in a patient with 18q deletion syndrome, primary immune deficiency, and type 1 diabetes. [PDF]

open access: yesInt J Immunopathol Pharmacol, 2021
Hogendorf A   +6 more
europepmc   +1 more source

Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

open access: yesAdvanced Science, EarlyView.
A multifunctional mPDZM nanoplatform is developed in this study. mPDZM integrates chemotherapy‐induced senescence, selective senolysis, and STING‐mediated immune activation. mPDZM effectively clears senescent tumor cells, remodels the tumor immune microenvironment, and enhances antitumor T‐cell responses.
Shiji Fang   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy